Literature DB >> 19935829

The (CAG)n tract of Machado-Joseph Disease gene (ATXN3): a comparison between DNA and mRNA in patients and controls.

Conceição Bettencourt1, Cristina Santos, Rafael Montiel, Teresa Kay, João Vasconcelos, Patrícia Maciel, Manuela Lima.   

Abstract

Machado-Joseph disease (MJD) is an autosomal dominant neurodegenerative disorder of late onset (occurring at a mean age of 40.2 years). The clinical manifestation of MJD is dependent on the presence of an expansion of the (CAG)(n) motif within exon 10 of the ATXN3 gene, located at 14q32.1. The variance in onset of MJD is only partially correlated (approximately 50-80%) with the extension of the CAG tract in genomic DNA (gDNA). The main aim of this work was to determine whether there are discrepancies in the size of the (CAG)(n) tract between gDNA and mRNA, and to establish whether there is a better association between age at onset and repeat size at the mRNA level. We typed gDNA and cDNA samples for the (CAG)(n) tract totalizing 108 wild-type and 52 expanded ATXN3 alleles. In wild-type alleles no differences were found between gDNA and cDNA. In expanded alleles, the CAG repeat size in gDNA was not always directly transcribed into the mRNA; on average there were differences of +1 repeat at the cDNA level. The slight discrepancies obtained were insufficient to cause significant differences in the distribution of the expanded alleles, and therefore no improvement in onset variance explanation was obtained with mRNA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935829      PMCID: PMC2987309          DOI: 10.1038/ejhg.2009.215

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  14 in total

1.  Intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype.

Authors:  N van Alfen; R J Sinke; M J Zwarts; A Gabreëls-Festen; P Praamstra; B P Kremer; M W Horstink
Journal:  Ann Neurol       Date:  2001-06       Impact factor: 10.422

2.  The genomic structure and expression of MJD, the Machado-Joseph disease gene.

Authors:  Y Ichikawa; J Goto; M Hattori; A Toyoda; K Ishii; S Y Jeong; H Hashida; N Masuda; K Ogata; F Kasai; M Hirai; P Maciel; G A Rouleau; Y Sakaki; I Kanazawa
Journal:  J Hum Genet       Date:  2001       Impact factor: 3.172

3.  Triplet repeat DNA structures and human genetic disease: dynamic mutations from dynamic DNA.

Authors:  Richard R Sinden; Vladimir N Potaman; Elena A Oussatcheva; Christopher E Pearson; Yuri L Lyubchenko; Luda S Shlyakhtenko
Journal:  J Biosci       Date:  2002-02       Impact factor: 1.826

4.  Improvement in the molecular diagnosis of Machado-Joseph disease.

Authors:  P Maciel; M C Costa; A Ferro; M Rousseau; C S Santos; C Gaspar; J Barros; G A Rouleau; P Coutinho; J Sequeiros
Journal:  Arch Neurol       Date:  2001-11

5.  CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1.

Authors:  Y Kawaguchi; T Okamoto; M Taniwaki; M Aizawa; M Inoue; S Katayama; H Kawakami; S Nakamura; M Nishimura; I Akiguchi
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

6.  Transcription and nuclear transport of CAG/CTG trinucleotide repeats in yeast.

Authors:  Emmanuelle Fabre; Bernard Dujon; Guy-Franck Richard
Journal:  Nucleic Acids Res       Date:  2002-08-15       Impact factor: 16.971

7.  Analysis of segregation patterns in Machado-Joseph disease pedigrees.

Authors:  Conceição Bettencourt; Cristina Santos; Teresa Kay; João Vasconcelos; Manuela Lima
Journal:  J Hum Genet       Date:  2008-08-09       Impact factor: 3.172

Review 8.  Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis.

Authors:  Ludger Schöls; Peter Bauer; Thorsten Schmidt; Thorsten Schulte; Olaf Riess
Journal:  Lancet Neurol       Date:  2004-05       Impact factor: 44.182

9.  Correlation between CAG repeat length and clinical features in Machado-Joseph disease.

Authors:  P Maciel; C Gaspar; A L DeStefano; I Silveira; P Coutinho; J Radvany; D M Dawson; L Sudarsky; J Guimarães; J E Loureiro
Journal:  Am J Hum Genet       Date:  1995-07       Impact factor: 11.025

10.  Molecular features of the CAG repeats and clinical manifestation of Machado-Joseph disease.

Authors:  H Maruyama; S Nakamura; Z Matsuyama; T Sakai; M Doyu; G Sobue; M Seto; M Tsujihata; T Oh-i; T Nishio
Journal:  Hum Mol Genet       Date:  1995-05       Impact factor: 6.150

View more
  10 in total

1.  Parametric fMRI of paced motor responses uncovers novel whole-brain imaging biomarkers in spinocerebellar ataxia type 3.

Authors:  João Valente Duarte; Ricardo Faustino; Mercês Lobo; Gil Cunha; César Nunes; Carlos Ferreira; Cristina Januário; Miguel Castelo-Branco
Journal:  Hum Brain Mapp       Date:  2016-06-07       Impact factor: 5.038

Review 2.  Machado-Joseph Disease: from first descriptions to new perspectives.

Authors:  Conceição Bettencourt; Manuela Lima
Journal:  Orphanet J Rare Dis       Date:  2011-06-02       Impact factor: 4.123

3.  Sequence analysis of 5' regulatory regions of the Machado-Joseph disease gene (ATXN3).

Authors:  Conceição Bettencourt; Mafalda Raposo; Nadiya Kazachkova; Cristina Santos; Teresa Kay; João Vasconcelos; Patrícia Maciel; Karina C Donis; Maria Luiza Saraiva-Pereira; Laura B Jardim; Jorge Sequeiros; Jácome Bruges-Armas; Manuela Lima
Journal:  Cerebellum       Date:  2012-12       Impact factor: 3.847

4.  Evaluation of CAG repeat length of androgen receptor expressing cells in human testes showing different pictures of spermatogenic impairment.

Authors:  Daniela Fietz; Joachim Geyer; Sabine Kliesch; Jörg Gromoll; Martin Bergmann
Journal:  Histochem Cell Biol       Date:  2011-10-25       Impact factor: 4.304

5.  Transcript diversity of Machado-Joseph disease gene (ATXN3) is not directly determined by SNPs in exonic or flanking intronic regions.

Authors:  Conceição Bettencourt; Mafalda Raposo; Raquel Ros; Rafael Montiel; Jácome Bruges-Armas; Manuela Lima
Journal:  J Mol Neurosci       Date:  2012-06-16       Impact factor: 3.444

6.  Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.

Authors:  Maxinne Watchon; Luan Luu; Katherine J Robinson; Kristy C Yuan; Alana De Luca; Hannah J Suddull; Madelaine C Tym; Gilles J Guillemin; Nicholas J Cole; Garth A Nicholson; Roger S Chung; Albert Lee; Angela S Laird
Journal:  Mol Brain       Date:  2021-08-20       Impact factor: 4.041

7.  Physiological and pathophysiological characteristics of ataxin-3 isoforms.

Authors:  Daniel Weishäupl; Juliane Schneider; Barbara Peixoto Pinheiro; Corinna Ruess; Sandra Maria Dold; Felix von Zweydorf; Christian Johannes Gloeckner; Jana Schmidt; Olaf Riess; Thorsten Schmidt
Journal:  J Biol Chem       Date:  2018-11-19       Impact factor: 5.157

8.  Parkinsonian phenotype in Machado-Joseph disease (MJD/SCA3): a two-case report.

Authors:  Conceição Bettencourt; Cristina Santos; Paula Coutinho; Patrizia Rizzu; João Vasconcelos; Teresa Kay; Teresa Cymbron; Mafalda Raposo; Peter Heutink; Manuela Lima
Journal:  BMC Neurol       Date:  2011-10-24       Impact factor: 2.474

9.  Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide.

Authors:  Eleni Kourkouta; Rudie Weij; Anchel González-Barriga; Melissa Mulder; Ruurd Verheul; Sieto Bosgra; Bas Groenendaal; Jukka Puoliväli; Jussi Toivanen; Judith C T van Deutekom; Nicole A Datson
Journal:  Mol Ther Nucleic Acids       Date:  2019-07-19       Impact factor: 8.886

10.  A Novel Calpain Inhibitor Compound Has Protective Effects on a Zebrafish Model of Spinocerebellar Ataxia Type 3.

Authors:  Katherine J Robinson; Kristy Yuan; Stuart K Plenderleith; Maxinne Watchon; Angela S Laird
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.